Arbor Biotechnologies

Biotech & Life Sciences · Cambridge, United States · Founded 2016

Diverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – for accelerating the discovery of proteins for… MoreLess

Arbor Biotechnologies is an early-stage life sciences company at the forefront of biodiscovery. Leveraging cutting-edge technologies such as artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor is revolutionizing the discovery of proteins that can significantly improve human health and biotechnologies. The company is dedicated to developing curative genetic medicines for patients with serious genetic diseases by understanding the underlying genetic pathology of these conditions. Arbor's extensive toolbox of CRISPR-based genomic editors allows for tailored therapeutic approaches, unlocking advancements that have the potential to transform patient outcomes.

Arbor primarily serves the healthcare sector, focusing on patients with genetic disorders. The company operates within the biotechnology market, utilizing a business model that centers on research and development partnerships, such as its collaboration with Vertex Pharmaceuticals to develop ex vivo engineered cell therapies. Arbor generates revenue through these strategic partnerships and the commercialization of its proprietary CRISPR technology.

Keywords: CRISPR, genomic editors, genetic diseases, artificial intelligence, genome sequencing, gene synthesis, high-throughput screening, therapeutic advancements, biotechnology, healthcare.

Valuation $1–2.5B

Headcount 100–500

Total funding $100–500M

Unlock exact values

Company overview

Arbor Biotechnologies company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2016
Headquarters: Cambridge, United States
Employees: 103
Open positions: None listed
Dealroom signal: 63.8

Website ↗LinkedIn ↗

technologyArtificial IntelligencetechnologyDeep TechtechnologyMachine LearningtechnologyNanotechsub industryBioTechnologyindustryHealthsectorBiotechnologysectorDrug DevelopmentsectorDNAsectorGenetics and genomicssectorCore AIsectorCrisprsectorSpinoutsectorRumoured $1B

Valuation & funding

Arbor Biotechnologies funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Oct 2025	$0	—	Samsung Ventures	↗
SERIES COther financing	Mar 2025	$74M	$1.1B	Partners Investment · ArrowMark Partners · T. Rowe Price · Aberdeen	↗
SERIES BOther financing	Nov 2021	$215M	$860M	Tekla Capital Management · ARCH Venture Partners · Vertex Pharmaceuticals · Section 32	↗
EARLY VCOther financing	Jun 2017	$16M	$62M	Undisclosed	—
SPINOUTOther financing	Jan 2016	$0	—	Massachusetts Institute of Technology · Broad Institute · Harvard University	—

Showing 5 recorded eventsUnlock the complete deal history →

Growth signals

Arbor Biotechnologies website traffic

Latest recorded traffic for Arbor Biotechnologies is 8.1K monthly website visits, up 1.2% over the last three months. Arbor Biotechnologies's team declined 5.5% over the past year.

Latest monthly visits8.1K 3-month web change+1.2% 1-year team growth-5.5%

Monthly website visits105 observations · Oct 2017–Jul 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Hiring

Open positions at Arbor Biotechnologies

Current openings linked to this company in Dealroom.

Director, Regulatory AffairsCambridge, MA · Other · Sep 2, 2026 Senior Clinical Trial ManagerCambridge, MA · Other · Aug 6, 2026 Manager, Regulatory AffairsCambridge, MA · Legal · Jul 26, 2026 Associate Director, Biomarker & Assay DevelopmentCambridge, MA · Other · Jul 11, 2026 Senior Scientist, PharmacologyCambridge, MA · Other · Jul 11, 2026

5 distinct openings shownExplore hiring signals →

Comparisons

Arbor Biotechnologies compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DGDeep GenomicsDeep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies	Toronto, Canada	Operational	112	$237M	$720M
DTDyno TherapeuticsUtilizing next-gen DNA technologies and machine learning to engineer AAV capsids for effective delivery of gene therapies	Watertown, United States	Operational
CDC4X DiscoveryC4X Discovery - building the world's most productive drug discovery engine	Manchester, United Kingdom	Operational
MEMetagenomiDiscovering the next generation of gene-editing systems for use in treating genetic diseases	Emeryville, United States	Operational
SYSyntekabioAI driven drug discovery and development company	Seoul, South Korea	Operational
LTLodo TherapeuticsDrug discovery and development company	New York City, United States	Acquired
RPRecursion PharmaA clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery	Salt Lake City, United States	Operational
OPOppilotechComputational biology platform for first-in-class drug discovery	London, United Kingdom	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

Arbor Biotechnologies's talent

Book a demo to see the people

Team profiled 15 named & role-tagged

Founders /100 quality score

Key operators 6 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

29 investors on Arbor Biotechnologies's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 19 investors entered at this stage

Ally Bridge Group

TCGX

Temasek

Tekla Capital Management

ARCH Venture Partners

Vertex Pharmaceuticals

Section 32

ArrowMark Partners

T. Rowe Price

Woodline Partners

Tao Capital Partners

Citadel

Illumina Ventures

GreatPoint Ventures

Janus Henderson Investors

Ridgeback Capital

Logos Capital

Deep Track Capital

Piper Heartland Healthcare Capital

Series B+ 7 investors entered at this stage

Partners Investment

Aberdeen

Kerna Ventures

Qatar Investment Authority

Revelation Partners

Surveyor Capital

Samsung Ventures

Other known 3 additional known investors

Broad Institute

Harvard University

Massachusetts Institute of Technology

Global footprint

Where Arbor Biotechnologies has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

In the news

Latest news about Arbor Biotechnologies

Recent press, funding announcements, and product moves mentioning Arbor Biotechnologies — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Arbor Biotechnologies

An AI-synthesized read of the highest-engagement posts about Arbor Biotechnologies on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Arbor Biotechnologies’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.